| Name | Title | Contact Details |
|---|
Global Synergizers is a social impact consulting firm that collaborates with corporates, social product innovators and social organisations to enable collective impact. Our programs are aligned with UN SDGs and address issues at the local level to create a systemic effect. If you would like to collaborate with us, write to us on info@globalsynergizers.com.
We make pictures that sell your products.
Segerstrom Center for the Arts is a leading performing arts complex located in Costa Mesa, California. Established in 1986 and renamed in 2011, it spans 14 acres and is recognized as Orange County’s largest non-profit arts organization. The Center features multiple venues, including Segerstrom Hall, Renée and Henry Segerstrom Concert Hall, Samueli Theater, and Judy Morr Theater, hosting a wide range of performances. The Center offers live performances that include Broadway shows, classical concerts, dance, and contemporary acts. It also provides venue rentals for private events and seminars, along with arts-based education programs through the Lawrence and Kristina Dodge Education Center. With a mission focused on artistic excellence and community engagement, the Center has welcomed over 20 million visitors and premiered over 60 world-class productions since its inception.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Reos Partners (www.reospartners.com) is an international social enterprise that helps people move forward together on their most important and intractable issues. We design, facilitate, and guide processes that enable teams of stakeholders—even those who dont understand or agree with or trust one another—to make progress on their toughest challenges. Our approach is systemic, collaborative, and creative. We partner with governments, corporations, and civil society organizations on challenges such as education, health, food, energy, environment, development, justice, security, and peace. Our work is pragmatic, professional, and tailored to the needs of the specific situation. We operate both globally and locally, with offices in Cambridge (Massachusetts), Geneva, Johannesburg, Melbourne, Montréal, and São Paulo. Our name comes from the Greek "rheos," which means "flow."